Bolt Interest Income vs Cost Of Revenue Analysis

BOLT Stock

USD 0.64 0.01 1.59%

Bolt Biotherapeutics financial indicator trend analysis is way more than just evaluating Bolt Biotherapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bolt Biotherapeutics is a good investment. Please check the relationship between Bolt Biotherapeutics Interest Income and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bolt Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

Interest Income vs Cost Of Revenue

Interest Income vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bolt Biotherapeutics Interest Income account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Bolt Biotherapeutics' Interest Income and Cost Of Revenue is -0.75. Overlapping area represents the amount of variation of Interest Income that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Bolt Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Bolt Biotherapeutics' Interest Income and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Income of Bolt Biotherapeutics are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Interest Income i.e., Bolt Biotherapeutics' Interest Income and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.75

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Cost Of Revenue

Cost of Revenue is found on Bolt Biotherapeutics income statement and represents the costs associated with goods and services Bolt Biotherapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Bolt Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bolt Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bolt Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.Selling General Administrative is likely to drop to about 14.7 M in 2024. Issuance Of Capital Stock is likely to drop to about 276.4 K in 2024

	2021	2022	2023	2024 (projected)
Interest Income	281K	2.2M	6.2M	6.5M
Net Interest Income	281K	2.2M	6.2M	6.5M

Interest Income Net Interest Income

Bolt Biotherapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other
Total Assets		0.94	0.93	0.94	0.93	0.91	0.9	0.94	0.68	-0.81	0.95	0.22	0.98	0.75	0.38	0.99	0.78	-0.02	0.94	0.87	0.94	0.2	0.93	0.92	0.99	-0.1
Short Long Term Debt Total	0.94		0.96	0.99	0.78	0.9	0.82	1.0	0.76	-0.89	0.99	0.18	0.91	0.87	0.46	0.93	0.94	0.23	1.0	0.96	0.91	0.44	0.78	0.99	0.94	0.08
Other Current Liab	0.93	0.96		0.99	0.82	0.92	0.85	0.97	0.86	-0.92	0.96	-0.04	0.86	0.87	0.42	0.95	0.85	0.08	0.96	0.98	0.96	0.3	0.82	0.97	0.95	0.03
Total Current Liabilities	0.94	0.99	0.99		0.8	0.92	0.83	0.99	0.82	-0.92	0.99	0.08	0.89	0.89	0.44	0.94	0.91	0.17	0.99	0.98	0.94	0.39	0.8	0.99	0.94	0.07
Total Stockholder Equity	0.93	0.78	0.82	0.8		0.86	0.93	0.77	0.55	-0.7	0.83	0.2	0.89	0.54	0.1	0.94	0.53	-0.37	0.78	0.7	0.91	-0.16	1.0	0.77	0.94	-0.4
Other Liab	0.91	0.9	0.92	0.92	0.86		0.97	0.89	0.8	-0.96	0.92	0.06	0.87	0.78	0.11	0.91	0.77	-0.11	0.9	0.88	0.95	0.1	0.86	0.91	0.91	-0.19
Net Tangible Assets	0.9	0.82	0.85	0.83	0.93	0.97		0.8	0.67	-0.86	0.85	0.12	0.87	0.64	-0.02	0.9	0.61	-0.32	0.82	0.76	0.93	-0.12	0.93	0.82	0.9	-0.38
Property Plant And Equipment Net	0.94	1.0	0.97	0.99	0.77	0.89	0.8		0.79	-0.89	0.98	0.13	0.91	0.89	0.51	0.93	0.94	0.25	1.0	0.97	0.91	0.46	0.77	0.99	0.94	0.14
Net Debt	0.68	0.76	0.86	0.82	0.55	0.8	0.67	0.79		-0.89	0.73	-0.48	0.63	0.9	0.4	0.7	0.7	0.17	0.76	0.9	0.8	0.34	0.55	0.8	0.7	0.29
Retained Earnings	-0.81	-0.89	-0.92	-0.92	-0.7	-0.96	-0.86	-0.89	-0.89		-0.89	0.1	-0.76	-0.87	-0.17	-0.82	-0.82	-0.05	-0.89	-0.93	-0.9	-0.25	-0.7	-0.92	-0.82	0.02
Accounts Payable	0.95	0.99	0.96	0.99	0.83	0.92	0.85	0.98	0.73	-0.89		0.23	0.91	0.81	0.38	0.96	0.91	0.13	0.99	0.93	0.92	0.34	0.83	0.98	0.96	-0.04
Cash	0.22	0.18	-0.04	0.08	0.2	0.06	0.12	0.13	-0.48	0.1	0.23		0.27	-0.22	-0.09	0.19	0.21	0.04	0.18	-0.09	-0.02	0.06	0.2	0.1	0.18	-0.38
Non Current Assets Total	0.98	0.91	0.86	0.89	0.89	0.87	0.87	0.91	0.63	-0.76	0.91	0.27		0.75	0.4	0.94	0.77	0.04	0.91	0.82	0.89	0.25	0.89	0.9	0.94	-0.03
Non Currrent Assets Other	0.75	0.87	0.87	0.89	0.54	0.78	0.64	0.89	0.9	-0.87	0.81	-0.22	0.75		0.55	0.72	0.86	0.38	0.87	0.95	0.81	0.56	0.54	0.91	0.73	0.42
Other Assets	0.38	0.46	0.42	0.44	0.1	0.11	-0.02	0.51	0.4	-0.17	0.38	-0.09	0.4	0.55		0.35	0.54	0.75	0.46	0.5	0.24	0.81	0.1	0.45	0.36	0.79
Cash And Short Term Investments	0.99	0.93	0.95	0.94	0.94	0.91	0.9	0.93	0.7	-0.82	0.96	0.19	0.94	0.72	0.35		0.77	-0.06	0.93	0.87	0.94	0.16	0.94	0.92	1.0	-0.15
Common Stock Shares Outstanding	0.78	0.94	0.85	0.91	0.53	0.77	0.61	0.94	0.7	-0.82	0.91	0.21	0.77	0.86	0.54	0.77		0.51	0.94	0.91	0.73	0.68	0.53	0.93	0.77	0.29
Non Current Liabilities Total	-0.02	0.23	0.08	0.17	-0.37	-0.11	-0.32	0.25	0.17	-0.05	0.13	0.04	0.04	0.38	0.75	-0.06	0.51		0.23	0.26	-0.14	0.97	-0.37	0.22	-0.05	0.87
Capital Lease Obligations	0.94	1.0	0.96	0.99	0.78	0.9	0.82	1.0	0.76	-0.89	0.99	0.18	0.91	0.87	0.46	0.93	0.94	0.23		0.96	0.91	0.44	0.78	0.99	0.94	0.08
Other Current Assets	0.87	0.96	0.98	0.98	0.7	0.88	0.76	0.97	0.9	-0.93	0.93	-0.09	0.82	0.95	0.5	0.87	0.91	0.26	0.96		0.91	0.47	0.7	0.98	0.88	0.21
Other Stockholder Equity	0.94	0.91	0.96	0.94	0.91	0.95	0.93	0.91	0.8	-0.9	0.92	-0.02	0.89	0.81	0.24	0.94	0.73	-0.14	0.91	0.91		0.09	0.91	0.92	0.95	-0.14
Total Liab	0.2	0.44	0.3	0.39	-0.16	0.1	-0.12	0.46	0.34	-0.25	0.34	0.06	0.25	0.56	0.81	0.16	0.68	0.97	0.44	0.47	0.09		-0.16	0.44	0.17	0.83
Net Invested Capital	0.93	0.78	0.82	0.8	1.0	0.86	0.93	0.77	0.55	-0.7	0.83	0.2	0.89	0.54	0.1	0.94	0.53	-0.37	0.78	0.7	0.91	-0.16		0.77	0.94	-0.4
Property Plant And Equipment Gross	0.92	0.99	0.97	0.99	0.77	0.91	0.82	0.99	0.8	-0.92	0.98	0.1	0.9	0.91	0.45	0.92	0.93	0.22	0.99	0.98	0.92	0.44	0.77		0.92	0.11
Total Current Assets	0.99	0.94	0.95	0.94	0.94	0.91	0.9	0.94	0.7	-0.82	0.96	0.18	0.94	0.73	0.36	1.0	0.77	-0.05	0.94	0.88	0.95	0.17	0.94	0.92		-0.14
Non Current Liabilities Other	-0.1	0.08	0.03	0.07	-0.4	-0.19	-0.38	0.14	0.29	0.02	-0.04	-0.38	-0.03	0.42	0.79	-0.15	0.29	0.87	0.08	0.21	-0.14	0.83	-0.4	0.11	-0.14

Click cells to compare fundamentals

Bolt Biotherapeutics Account Relationship Matchups

Bolt Biotherapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	48.4M	46.5M	307.7M	227.8M	159.8M	147.8M
Short Long Term Debt Total	10.2M	10.9M	24.4M	22.6M	20.2M	16.2M
Other Current Liab	2.9M	5.2M	9.9M	12.7M	9.7M	7.7M
Total Current Liabilities	8.7M	11.3M	21.3M	23.1M	20.5M	16.1M
Total Stockholder Equity	(45.8M)	(104.9M)	250.1M	171.5M	112.7M	67.4M
Other Liab	1.0M	329K	14.4M	13.0M	14.9M	15.7M
Net Tangible Assets	(45.8M)	(104.9M)	250.1M	171.5M	197.2M	207.1M
Property Plant And Equipment Net	11.5M	16.4M	30.6M	28.5M	24.1M	20.6M
Net Debt	(24.6M)	5.3M	(3.0M)	13.4M	9.4M	9.9M
Retained Earnings	(47.7M)	(108.4M)	(207.0M)	(295.1M)	(364.3M)	(346.1M)
Accounts Payable	2.1M	1.6M	3.6M	3.6M	3.0M	2.7M
Cash	34.8M	5.5M	27.4M	9.2M	10.8M	13.5M
Non Current Assets Total	12.5M	21.2M	118.6M	55.1M	54.1M	48.3M
Non Currrent Assets Other	446K	3.2M	2.6M	2.6M	3.6M	2.4M
Other Assets	1.0M	4.8M	2.6M	2.6M	1.0	0.95
Cash And Short Term Investments	34.8M	22.8M	186.2M	168.9M	102.2M	96.9M
Common Stock Shares Outstanding	35.1M	36.2M	37.4M	37.4M	37.8M	35.4M
Liabilities And Stockholders Equity	48.4M	46.5M	307.7M	227.8M	159.8M	147.8M
Non Current Liabilities Total	85.6M	140.2M	36.3M	33.2M	26.6M	46.8M
Capital Lease Obligations	10.2M	10.9M	24.4M	22.6M	20.2M	16.2M
Other Current Assets	1.1M	2.5M	2.9M	3.9M	3.5M	2.6M
Other Stockholder Equity	(75.7M)	3.5M	457.4M	467.5M	477.0M	238.8M
Total Liab	94.3M	151.5M	57.6M	56.3M	47.0M	58.5M
Net Invested Capital	(45.8M)	(104.9M)	250.1M	171.5M	112.7M	67.4M
Property Plant And Equipment Gross	11.5M	16.4M	30.6M	28.5M	29.8M	21.7M
Total Current Assets	35.9M	25.4M	189.2M	172.7M	105.7M	99.5M
Non Current Liabilities Other	71K	25.6M	210K	42K	43K	40.9K
Net Working Capital	27.2M	14.1M	167.8M	149.6M	85.3M	83.5M
Short Term Debt	3.1M	3.0M	5.0M	4.8M	5.6M	3.9M
Property Plant Equipment	11.5M	16.4M	30.6M	28.5M	32.8M	19.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Bolt Stock Analysis

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC